Testing a PSMA dye to improve prostate biopsy
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new dye (AS1986NS) that sticks to prostate cancer cells during a biopsy. It aims to help doctors see cancer more clearly. You may be able to join if you are scheduled for a standard prostate biopsy and have no major health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are being checked for prostate cancer and need a standard prostate biopsy (multiple samples taken from the prostate).
- You are not currently receiving a specific type of radiation therapy called Lutetium-177 or Actinium-225 PSMA therapy.
- You do not have known serious problems with your liver, kidneys, or heart, and you do not have a fever.
- Your kidney function is normal (a test called creatinine clearance is above 60 mL/min).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
This study tests a new way to guide prostate biopsies using a special scan (PSMA PET/CT) that highlights suspicious areas. If you need a biopsy because of high PSA and abnormal MRI, this approach might help make the biopsy more accurate.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.